2013 - Pharmacist Digest

NPPA monitors the prices of scheduled as well as non-scheduled medicines under DPCO, 2013

Express Pharma

JULY 31, 2024

According to the statement published by PIB, The National Pharmaceutical Pricing Authority (NPPA) is actively overseeing the pricing of both scheduled and non-scheduled medicines under the Drugs (Prices Control) Order, 2013 (DPCO, 2013). Under DPCO, 2013, formulations are categorised into scheduled and non-scheduled drugs.

Drug Pricing

Pumping breastmilk in bathrooms is a common, albeit unspoken, practice at health care conferences

STAT

JANUARY 18, 2024

This was back in 2013, when such accommodations were a rarity. Even though Erin Booth was not thrilled about having to travel to Philadelphia for a conference at six weeks postpartum, this one at least advertised having a private lactation space.

Opinion: To overcome the overdose crisis, addiction treatment must be integrated into the health care system

STAT

JULY 19, 2024

The first time I saw Maya (not her real name) huddled under blankets in a hospital bed in 2013, she had been to dozens of inpatient detox programs and residential treatment centers since she had begun using heroin two decades earlier. After every release, she returned to heroin use, usually within days.

Inpatient

Inpatient Hospitals

Webinars

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

MORE WEBINARS

STAT+: AI drug firm Recursion moves from survival to industry domination

STAT

AUGUST 19, 2024

The company — or, at least, what existed at its founding in 2013 — hoped to pull data from images of healthy and diseased cells, and use that data to identify drugs gathering dust on pharmaceutical company shelves that could be repurposed as rare disease treatments.

Medical Schools

Medical Schools Drug Development Pharmaceutical Companies Pharmaceutical Companies

Q&A: The scientific integrity sleuth taking on the widespread problem of research misconduct

STAT

FEBRUARY 28, 2024

Bik first became interested in plagiarism as a hobby while working as a researcher at Stanford University in 2013. She later began specializing in image duplication specifically, which she believes is a more serious problem for science as a whole. Read the rest…

Opinion: How I fought Big Pharma on insulin prices — and won

STAT

SEPTEMBER 20, 2024

In 2013, I sat down at my computer and secured the URL t1international.com. I wanted a place where I could collect and share everything I was learning about the global insulin price crisis. I was only 25 years old, and I had already been living with type 1 diabetes for more than two decades.

Diabetes

Diabetes Hospitals

STAT+: Goldman Sachs launches $650 million fund for life science investments

STAT

JANUARY 3, 2024

billion was raised by 183 new VC funds, which was the lowest fundraising total for first-timers since 2013, according to Pitchbook. First-time funds have been difficult to raise during the biotech downturn. Last year, around $11.6 Around $25.6 billion had been raised by 556 first-time funds in 2022.

STAT+: Payments by drug and device makers to doctors remain widespread, but also vary considerably

STAT

MARCH 28, 2024

From 2013 to 2022, pharmaceutical and device companies made more than 85 million payments totaling $12.1 The financial ties between drug and device makers and some physicians remains pervasive, despite concerns such relationships may influence medical practice, according to a new analysis of payments made over a recent 10-year span.

STAT+: CRISPR’s pioneers reflect on the first gene-editing treatment

STAT

NOVEMBER 18, 2023

It wasn’t until January 2013 that the first paper showing the enzyme would work in cells, from Feng Zhang, was published, also in Science. Jennifer Doudna and Emmanuelle Charpentier, now Nobelists , published their first paper announcing a new enzyme for editing DNA in Science in June 2012. It was called CRISPR-Cas9.

STAT+: A Q&A with the CEO of CRISPR Therapeutics on a historic approval and the road ahead

STAT

DECEMBER 8, 2023

Editas Medicine, CRISPR Therapeutics, and Intellia Therapeutics were all started in the 2013-2014 time frame with the same goal of turning the nascent CRISPR gene-editing technology into medicines.

STAT+: AbbVie CEO Gonzalez to step down after a decade fiercely defending its top seller, Humira

STAT

FEBRUARY 20, 2024

AbbVie announced Tuesday that CEO Richard Gonzalez, who has managed the company’s ascent since it was spun off from the device maker Abbott Laboratories in 2013, will step down in July.

Biosimilars

STAT+: Life sciences deals on track to hit lowest point since 2017

STAT

OCTOBER 11, 2023

So far this year, there have been 1,384 VC deals struck in the field, the lowest figure since 2013. New data from Pitchbook and the National Venture Capital Association show that both the number of deals and the amount of money that’s being invested in life science companies are down significantly.

STAT+: A flurry of research misconduct cases has universities scrambling to protect themselves

STAT

FEBRUARY 12, 2024

Over the past decade, the number of research misconduct allegations reported to the National Institutes of Health has more than doubled, climbing from 74 in 2013 to 169 in 2022. And it’s hardly alone. And scientific sleuths are finding plenty of other problems that don’t always qualify as outright misconduct.

STAT+: About half of cancer drugs given accelerated approval don’t improve survival or quality of life

STAT

APRIL 7, 2024

In 2013, it took an average of 9.9 In some cases, failure to show clinical benefit didn’t stop the FDA from converting accelerated approvals into full approvals, and the authors note the agency’s conversion decisions have increasingly been based on less stringent evidence of a drug’s benefits.

Diabetes treatments are improving. Racial disparities are wider than ever

STAT

DECEMBER 20, 2022

For example, the share of Mexican Americans taking insulin who achieved good blood-sugar control sharply dropped to 10% during the period of 2013 to 2020 from 25% during 1988 to 1994, researchers reported Tuesday in JAMA Network Open. Read the rest…

Diabetes

STAT+: Endo Health ordered to pay more than $1.5 billion in opioid criminal case

STAT

MAY 7, 2024

The company, which last month pleaded guilty to a misdemeanor, admitted that, from April 2012 through May 2013, some of its sales representatives marketed its medicine, also known as oxymorphone, to doctors by touting the drug as abuse deterrent, as well as resistant to tampering and crushing.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceutical Companies

Opinion: Bashing accelerated approval isn’t supported by the data

STAT

APRIL 23, 2024

Case in point: Under the seemingly benign title, “Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval,” an article published recently in the Journal of the American Medical Association claims that among “cancer drugs granted accelerated approval from 2013 to 2017, 41% (19/46) did not improve (..)

Drug Development

STAT+: Jeff Jonas leaves Sage Therapeutics to launch biotech incubator

STAT

NOVEMBER 10, 2022

He has been part of the C-suite at Sage Therapeutics since 2013. Longtime Sage Therapeutics executive Jeff Jonas is leaving the biotech company to launch a biotech incubator with global investment giant CBC Group. Sage announced this week that Jonas would leave the company to join a private equity firm. billion deal with Biogen.

STAT+: Drug industry payments to eye docs boosted Medicare spending on pricier treatments

STAT

SEPTEMBER 28, 2023

million from 2013 to 2019, presumably due to the company payments, according to the study, which was published in JAMA Health Forum. Physicians who did not accept payments prescribed Avastin 46% of the time, nearly twice as often as those who accepted payments. As a result, Medicare shelled out an estimated $642.8

STAT+: Pear Therapeutics sold for parts at $6 million auction

STAT

MAY 19, 2023

Founded in 2013, Pear was the most prominent company developing prescription digital therapeutics, or Food and Drug Administration-cleared software applications ordered by doctors to treat health conditions. Click Therapeutics, Welt Corp, Harvest Bio, and Nox Health Group each acquired bits of the company for $6.05

Study points to weaknesses in FDA accelerated approval path

pharmaphorum

APRIL 8, 2024

Less than half of the cancer therapies given accelerated approval by the FDA in 2013 to 2017 showed a clinical benefit in a confirmatory trial within the next five years

STAT+: Carbon Health blasts a major insurer in rare public dispute over coverage

STAT

MAY 1, 2023

San Francisco-based Carbon said that Elevance — formerly known as Anthem, which operates the Anthem Blue Cross plan in California — had refused to increase its payment rate in the state beyond 2013 levels, which was “no longer tenable as a livable wage.” ” Continue to STAT+ to read the full story…

STAT+: Freespira bets on slow and steady, amid spectacular digital health collapses

STAT

JUNE 18, 2024

based company was founded in 2013 and has raised $60 million to date. Perekupka said Freespira hopes to enroll 2,500 people in its treatment this year — twice last year’s sales — and to double its patients again in 2025 and 2026. The Kirkland, Wash.-based

Opinion: Use warranties, not outcomes-based agreements, to make payers whole when a gene therapy fails

STAT

MARCH 9, 2023

In the spring of 2013, I had just visited a lab focused on gene and cell therapies at Baylor College of Medicine. Bluebird Bio , which would soon launch a successful IPO , had licensed its technology from the same lab and was about to announce a major collaboration with Celgene and Baylor.

STAT+: FDA and large compound pharmacies settle a long-running dispute over a key list for ingredients

STAT

OCTOBER 12, 2022

A federal law that went into effect in 2013 requires the FDA to identify ingredients needed to satisfy an unmet “clinical need” and to include those on a list for use by large compounding pharmacies.

Compounding Pharmacies

Compounding Pharmacies Compounding

Opinion: Compounding pharmacies offer a fix for shortages of essential drugs

STAT

MAY 15, 2023

Hospitals ran short of essential treatment medications and were unable to source those drugs from manufacturers or from the outsourcing facilities that had been authorized by Congress in 2013 to “fill the gap” in such situations.

Compounding Pharmacies

Compounding Pharmacies Compounding Hospitals

STAT+: Study points to new ‘king on the block’ for treatment of chronic lymphocytic leukemia

STAT

DECEMBER 13, 2022

When it hit the market in 2013, the drug revolutionized the treatment of these cancers and represented a major step forward from chemotherapy and some other drugs at the time. NEW ORLEANS – One of the best therapies for some types of lymphoma and leukemia has been a drug called ibrutinib, made by AbbVie.

Chemotherapy

UK children shorter, more obese and less healthy than 20 years ago

The Pharmacist

JUNE 27, 2024

A report from the Food Foundation found the height of five-year olds has been falling since 2013, with UK children now shorter than those in nearly […] The post UK children shorter, more obese and less healthy than 20 years ago appeared first on The Pharmacist.

Diabetes

Opinion: The decline and fall of elite multispecialty medical groups

STAT

JANUARY 17, 2024

Central Texas’ Scott and White was absorbed into Baylor in 2013. Wisconsin’s Marshfield Clinic agreed to merge with Duluth-based Essentia Health in October 2022 after a lengthy string of operating losses, though the merger fell apart recently.

Hospitals

STAT+: Former Sage executives join biotech VC Cure Ventures

STAT

JANUARY 8, 2024

The two men worked together from 2013 until 2022, when Jonas left to start a biotech incubator with funding from investment giant CBC Group. The VC firm has hired Jeff Jonas, Sage’s former chief executive, and Al Robichaud, Sage’s former chief scientific officer, as partners, the team told STAT exclusively.

Labelling

Opinion: Former Sen. Max Baucus: Breakthrough Alzheimer’s drugs are out of reach for many in rural states like Montana

STAT

AUGUST 3, 2023

In his 2013 State of the Union address, he laid out a bold vision to fund and accelerate brain research: “If we want to make the best products, we also have to invest in the best ideas.

STAT+: Former Magellan Diagnostics execs charged with selling defective lead testing machines used for kids

STAT

APRIL 5, 2023

are charged with knowingly selling defective lead testing machines between 2013 and 2017 that generated inaccurate results for tens of thousands of children across the country and for clients of at least one international relief organization, federal prosecutors said. Three former executives at Magellan Diagnostics Inc.

STAT+: Mid-year drug price hikes are back despite Inflation Reduction Act

STAT

AUGUST 24, 2023

Indeed, on July 1, drugmakers raised the wholesale price on over 123 drugs in what’s the largest number of mid-year price hikes since 2013, according to data from drug pricing nonprofit 46brooklyn and the Elsevier Gold Standard Drug Database. Continue to STAT+ to read the full story…

Drug Pricing

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies

STAT+: KRAS, the ideal cancer drug target that became ‘undruggable,’ takes on a new glow

STAT

AUGUST 30, 2023

In 2013, Kevan Shokat, a biologist at the University of California, San Francisco, discovered a key chemical vulnerability in a specific subset of mutant oncogenic KRAS that made it possible to design small molecules that would bind to the protein. ” In the last few years, that attitude has sharply turned around.

Drug Development

2024 BCPS Exam – What’s Changing?

Med Ed 101

OCTOBER 4, 2023

It’s hard to believe that I have been following pharmacist board certifications and helping pharmacists pass the BCPS exam for over 10 years since I first passed it in 2013! Each year in updating and creating our study materials, I review the content outline and any possible changes in the BCPS exam.

AbbVie announces its new CEO

European Pharmaceutical Review

FEBRUARY 23, 2024

Richard Gonzalez will retire as the company’s CEO to become Executive Chairman, having served as the company’s CEO since its launch in 2013, AbbVie noted. Richard has facilitated AbbVie securing a market capitalisation increase from $54 billion in 2013 to over $300 billion in 2024.

Hospitals

Accord BioPharma’s Biosimilar IMULDOSA gains USFDA approval for treatment of chronic inflammatory conditions

Express Pharma

OCTOBER 14, 2024

IMULDOSA was initially developed as DMB-3115 in 2013 by Dong-A Socio Holdings and Meiji Seika Pharma. In 2021, Intas Pharmaceuticals acquired exclusive commercialisation rights to DMB-3115 through a license agreement. As a global subsidiary of Intas Pharmaceuticals, Accord BioPharma will be responsible for US commercialisation of IMULDOSA.

Biosimilars

A review of changing regulatory and analytical requirements of free amino acid monographs of the European Pharmacopoeia

Pharmaceutical Technology

MARCH 12, 2024

Butterworth Laboratories looks at the current amino acid testing landscape since the changes in monographs introduced in 2013.

ACMT Toxicology Visual Pearl: Salt, not Shock

ALiEM - Pharm Pearls

FEBRUARY 20, 2024

2013 Dec;15(4):90-2. Epub 2013 Nov 7. Sivalingam SK, Gadiraju VT, Hariharan MV, Atreya AR, Flack JE, Aziz H. Flecainide toxicity–treatment with intravenous fat emulsion and extra corporeal life support. Acute Card Care. doi: 10.3109/17482941.2013.841949. PMID: 24200150. Bruccoleri RE, Burns MM. J Med Toxicol.

SAEM Clinical Images Series: Man with a Recurrent Rash

ALiEM - Pharm Pearls

NOVEMBER 10, 2023

2013 Apr;168(4):726-32. Epub 2013 Feb 16. PMID: 34212341 Lipowicz S, Sekula P, Ingen-Housz-Oro S, Liss Y, Sassolas B, Dunant A, Roujeau JC, Mockenhaupt M. Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. doi: 10.1111/bjd.12133. PMID: 23413807.

Fact Sheet: Physicians Oppose S.2305 -That Would Make All Biosimilars Interchangeable

Safe Biologics

AUGUST 27, 2024

From 2013-2021 all 50 state legislatures passed laws restricting automatic pharmacy substitution of biosimilars ONLY to interchangeable biosimilars. The interchangeable standard’s data requirements provide that assurance, making a majority (59%) of U.S. physicians more comfortable with a pharmacy-level substitution.

Biosimilars

STAT+: Exact Sciences touts accuracy of updated Cologuard cancer test, but experts want more data

STAT

JUNE 20, 2023

A 2013 trial of the first iteration of Cologuard, known as DeeP-C, showed the test is 92% sensitive and 87% specific. The new Cologuard test correctly detected cancer 94% of the time, and it correctly returned a negative result 91% of the time, test characteristics known as sensitivity and specificity, respectively.

Increase in smoking among more affluent young women in past decade

The Pharmacist

APRIL 30, 2024

Data collected through a monthly survey that has involved almost 200,000 adults showed an increase in smoking prevalence from 12% to 15% in more socially advantaged women aged 18 to 45 years between 2013 and 2023. […] The post Increase in smoking among more affluent young women in past decade appeared first on The Pharmacist.

Opinion: STAT+: The PATCH Act’s approach to securing medical devices actually gives malicious actors a blueprint

STAT

NOVEMBER 7, 2023

In August 2013, the FDA made news when it issued cybersecurity guidance for medical devices.

NPPA monitors the prices of scheduled as well as non-scheduled medicines under DPCO, 2013

Pumping breastmilk in bathrooms is a common, albeit unspoken, practice at health care conferences

Webinars

Trending Sources

Opinion: To overcome the overdose crisis, addiction treatment must be integrated into the health care system

Webinars

STAT+: AI drug firm Recursion moves from survival to industry domination

Q&A: The scientific integrity sleuth taking on the widespread problem of research misconduct

Opinion: How I fought Big Pharma on insulin prices — and won

STAT+: Goldman Sachs launches $650 million fund for life science investments

STAT+: Payments by drug and device makers to doctors remain widespread, but also vary considerably

STAT+: CRISPR’s pioneers reflect on the first gene-editing treatment

STAT+: A Q&A with the CEO of CRISPR Therapeutics on a historic approval and the road ahead

STAT+: AbbVie CEO Gonzalez to step down after a decade fiercely defending its top seller, Humira

STAT+: Life sciences deals on track to hit lowest point since 2017

STAT+: A flurry of research misconduct cases has universities scrambling to protect themselves

STAT+: About half of cancer drugs given accelerated approval don’t improve survival or quality of life

Diabetes treatments are improving. Racial disparities are wider than ever

STAT+: Endo Health ordered to pay more than $1.5 billion in opioid criminal case

Opinion: Bashing accelerated approval isn’t supported by the data

STAT+: Jeff Jonas leaves Sage Therapeutics to launch biotech incubator

STAT+: Drug industry payments to eye docs boosted Medicare spending on pricier treatments

STAT+: Pear Therapeutics sold for parts at $6 million auction

Study points to weaknesses in FDA accelerated approval path

STAT+: Carbon Health blasts a major insurer in rare public dispute over coverage

STAT+: Freespira bets on slow and steady, amid spectacular digital health collapses

Opinion: Use warranties, not outcomes-based agreements, to make payers whole when a gene therapy fails

STAT+: FDA and large compound pharmacies settle a long-running dispute over a key list for ingredients

Opinion: Compounding pharmacies offer a fix for shortages of essential drugs

STAT+: Study points to new ‘king on the block’ for treatment of chronic lymphocytic leukemia

UK children shorter, more obese and less healthy than 20 years ago

Opinion: The decline and fall of elite multispecialty medical groups

STAT+: Former Sage executives join biotech VC Cure Ventures

Opinion: Former Sen. Max Baucus: Breakthrough Alzheimer’s drugs are out of reach for many in rural states like Montana

STAT+: Former Magellan Diagnostics execs charged with selling defective lead testing machines used for kids

STAT+: Mid-year drug price hikes are back despite Inflation Reduction Act

STAT+: KRAS, the ideal cancer drug target that became ‘undruggable,’ takes on a new glow

2024 BCPS Exam – What’s Changing?

AbbVie announces its new CEO

Accord BioPharma’s Biosimilar IMULDOSA gains USFDA approval for treatment of chronic inflammatory conditions

A review of changing regulatory and analytical requirements of free amino acid monographs of the European Pharmacopoeia

ACMT Toxicology Visual Pearl: Salt, not Shock

SAEM Clinical Images Series: Man with a Recurrent Rash

Fact Sheet: Physicians Oppose S.2305 -That Would Make All Biosimilars Interchangeable

STAT+: Exact Sciences touts accuracy of updated Cologuard cancer test, but experts want more data

Increase in smoking among more affluent young women in past decade

Opinion: STAT+: The PATCH Act’s approach to securing medical devices actually gives malicious actors a blueprint

Stay Connected